Private company
Canagold Resources
Mining company developing the New Polaris high-grade gold project in British Columbia., Canada.1
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
5.7%Gross margin2
-57.6%Operating margin2
-20.4%Net margin2
26.6%Revenue growth, 20252
-$36.9MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Health Care brought in 64% of the revenue Canagold Resources broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Health Care | 218.6M CNY | 188.1M CNY | 294.2M CNY |
| Medicine income | 100.5M CNY | 82.1M CNY | 79.7M CNY |
| Medical solution | 178.4M CNY | 99.2M CNY | 70.2M CNY |
| Management services and technical services | 23.2M CNY | 5.2M CNY | 10.2M CNY |
| Equipment Leasing Revenues | 16.7M CNY | 9.4M CNY | 6.2M CNY |
Business segments
Hospital brought in 81% of the revenue Canagold Resources broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Hospital | 319.1M CNY | 270.2M CNY | 373.9M CNY |
| Network | 218.3M CNY | 113.7M CNY | 86.6M CNY |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue96¢$62.2M
- Other costs3¢$1.9M
- Income tax1¢$867.0K
Out of $65.0M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues, net of value-added tax | 460.5M CNY | 384.0M CNY | 537.4M CNY |
| Cost of revenues | -434.7M CNY | -463.1M CNY | -614.0M CNY |
| Gross loss | 25.8M CNY | -79.2M CNY | -76.6M CNY |
| Selling expenses | -52.2M CNY | -48.6M CNY | -56.3M CNY |
| General and administrative expenses | -213.0M CNY | -404.4M CNY | -330.1M CNY |
| Impairment of long-term investments | -22.2M CNY | ||
| Operating loss | -261.5M CNY | -532.2M CNY | -463.0M CNY |
| Foreign exchange (loss) gain, net | -12.0M CNY | -17.5M CNY | 10.1M CNY |
| Change in fair value of derivative liability | 166.0K CNY | 5.2M CNY | |
| Income from equity method investments | 13.0M CNY | 12.7M CNY | 20.8M CNY |
| Loss on disposal of a subsidiary | 48.5M CNY | -638.0K CNY | |
| Other expenses, net | -7.7M CNY | -9.3M CNY | -10.8M CNY |
| Gain/ (loss) on sale of partial interests in an equity method investment | 37.5M CNY | -120.0K CNY | 37.5M CNY |
| Changes in fair value of short-term investments | 7.3M CNY | ||
| Loss before income tax | -373.4M CNY | -669.6M CNY | -555.6M CNY |
| Income tax benefit/(expense) | -6.1M CNY | 17.5M CNY | 24.6M CNY |
| Net loss | -379.4M CNY | -652.1M CNY | -531.0M CNY |
| Net loss attributable to noncontrolling interests | 286.6M CNY | 343.8M CNY | 233.4M CNY |
| Net loss attributable to Concord Medical Services Holdings Limited | -92.8M CNY | -308.2M CNY | -297.7M CNY |
| Basic | -0.71 CNY | -2.35 CNY | -2.27 CNY |
| Diluted | -0.71 CNY | -2.35 CNY | -2.27 CNY |
| Basic | 131.1M shares | 131.1M shares | 131.1M shares |
| Diluted | 131.1M shares | 131.1M shares | 131.1M shares |
| Foreign currency translation, net tax of nil | 16.4M CNY | -7.6M CNY | -6.5M CNY |
| Unrealized losses on available-for-sale securities, net | -14.6M CNY | -4.3M CNY | -31.2M CNY |
| Total other comprehensive income (loss), net of tax | 1.8M CNY | -11.9M CNY | -37.7M CNY |
| Comprehensive loss | -377.6M CNY | -664.0M CNY | -568.7M CNY |
| Comprehensive loss attributable to noncontrolling interests | -286.6M CNY | -343.8M CNY | -233.4M CNY |
| Comprehensive loss attributable to Concord Medical Services Holdings Limited | -91.0M CNY | -320.2M CNY | -335.3M CNY |
| Interest expense | 152.3M CNY | 193.2M CNY | 165.7M CNY |
| Interest income | 9.7M CNY | 14.0M CNY | 10.8M CNY |
| Foreign currency translation, net of tax | 0 CNY | 0 CNY | 0 CNY |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 297.8M CNY | 216.2M CNY | |
| Restricted cash | 921.0K CNY | 20.8M CNY | |
| Short-term investment | 1.0K CNY | 134.6M CNY | |
| Accounts receivable (net of allowance of RMB42,884 and RMB46,156 (US$6,600) and including amounts due from related parties amounting to RMB715 and RMB961 (US$137) as of December 31, 2024 and 2025, respectively) | 44.0M CNY | 51.2M CNY | |
| Prepayments and other current assets (net of reserve of RMB174,666 and RMB162,132 (US$23,184) and including amounts due from related parties amounting to RMB119,254 and RMB109,899 (US$15,715) as of December 31, 2024 and 2025, respectively) | 553.2M CNY | 527.8M CNY | |
| Inventories | 46.0M CNY | 33.4M CNY | |
| Total current assets | 941.9M CNY | 984.0M CNY | |
| Property, plant and equipment, net | 3.7B CNY | 3.7B CNY | |
| Right-of-use assets, net | 496.4M CNY | 520.8M CNY | |
| Goodwill | 572.2M CNY | 572.2M CNY | 575.4M CNY |
| Intangible assets, net | 255.9M CNY | 292.1M CNY | |
| Deposits for non-current assets | 129.6M CNY | 174.9M CNY | |
| Long-term investments | 422.0M CNY | 472.2M CNY | |
| Other non-current assets | 4.7M CNY | 5.9M CNY | |
| Total non-current assets | 5.6B CNY | 5.7B CNY | |
| Total assets | 6.5B CNY | 6.7B CNY | |
| Accounts payable | 119.3M CNY | 199.4M CNY | |
| Accrued expenses and other liabilities including loan from related party of RMB1,937 and RMB2,245 (US$321) as of December 31, 2024 and 2025, respectively) | 804.6M CNY | 846.2M CNY | |
| Income tax payable | 7.6M CNY | 1.6M CNY | |
| Operating lease liabilities, current | 41.9M CNY | 45.4M CNY | |
| Short-term bank and other borrowings (including loan from related party of RMB115,693 and RMB120,398 (US$17,217) as of December 31, 2024 and 2025, respectively) | 430.4M CNY | 649.7M CNY | |
| Long-term bank and other borrowings, current portion (including loan from related party of RMB17,517 and RMB47,356 (US$6,772) as of December 31, 2024 and 2025, respectively) | 550.7M CNY | 383.0M CNY | |
| Total current liabilities | 2.0B CNY | 2.1B CNY | |
| Long-term bank and other borrowings, non-current portion (including loan from related party of RMB95,493 and RMB103,216 (US$14,760) as of December 31, 2024 and 2025, respectively) | 2.5B CNY | 2.7B CNY | |
| Deferred tax liabilities | 75.0M CNY | 82.9M CNY | |
| Operating lease liabilities, non-current | 126.5M CNY | 138.9M CNY | |
| Other long-term liabilities | 75.8M CNY | 67.8M CNY | |
| Total non-current liabilities | 2.7B CNY | 3.0B CNY | |
| Total liabilities | 4.7B CNY | 5.1B CNY | |
| Treasury stock (12,101,847 and 12,101,847 shares as of December 31, 2024 and 2025, respectively) | -7.0K CNY | -7.0K CNY | |
| Additional paid-in capital | 2.4B CNY | 2.2B CNY | |
| Accumulated other comprehensive loss | -75.6M CNY | -77.3M CNY | |
| Accumulated deficit | -4.5B CNY | -4.4B CNY | |
| Total Concord Medical Services Holdings Limited shareholders' deficit | -2.1B CNY | -2.3B CNY | |
| Noncontrolling interests | 4.0B CNY | 3.9B CNY | |
| Total equity | 1.9B CNY | 1.6B CNY | 1.7B CNY |
| Total liabilities and equity | 6.5B CNY | 6.7B CNY | |
| Accounts receivable, allowance | 46.2M CNY | 42.9M CNY | |
| Reserve for prepayments and other current assets | 162.1M CNY | 174.7M CNY | |
| Treasury stock, common shares | 12.1M shares | 12.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -379.4M CNY | -652.1M CNY | -531.0M CNY |
| Depreciation of property, plant and equipment (note 10) | 103.5M CNY | 84.8M CNY | 82.1M CNY |
| Amortization of intangible assets (note 13) | 36.1M CNY | 36.4M CNY | 36.7M CNY |
| Amortization of land lease payments (note 11) | 9.6M CNY | 9.6M CNY | 9.6M CNY |
| Lease expense to reduce operating lease ROU | 14.8M CNY | 22.6M CNY | 26.7M CNY |
| Income from equity method investments | -13.0M CNY | -12.7M CNY | -20.8M CNY |
| Change in fair value of derivative liability | -166.0K CNY | -5.2M CNY | |
| Changes in fair value of short-term investments | -7.3M CNY | ||
| (Gain) loss on disposal of long-lived assets | 2.1M CNY | 13.1M CNY | -62.0K CNY |
| Deferred tax expense (benefit) | -7.9M CNY | -15.7M CNY | -13.0M CNY |
| Allowance for doubtful accounts, net | -6.9M CNY | 128.2M CNY | 64.7M CNY |
| Impairment of long-term investments | 22.2M CNY | ||
| Provision of Inventory write down | 52.0K CNY | ||
| Interest and consultation expenses | 152.3M CNY | 193.2M CNY | 165.7M CNY |
| (Gain) Loss on disposal of subsidiaries (note 4) | -48.5M CNY | 638.0K CNY | |
| Gain on sale of partial interests in equity method investment | -37.5M CNY | 120.0K CNY | -37.5M CNY |
| Accounts receivable | 6.1M CNY | 12.0M CNY | 36.5M CNY |
| Prepayments and other current assets | 161.3M CNY | -335.7M CNY | -149.7M CNY |
| Inventories | -12.6M CNY | 6.5M CNY | 44.5M CNY |
| Other non-current assets | -958.0K CNY | -458.0K CNY | 1.6M CNY |
| Accounts payable | -122.3M CNY | 93.1M CNY | 15.8M CNY |
| Accrued expenses and other liabilities | -165.6M CNY | 97.5M CNY | 70.8M CNY |
| Deferred revenue | 39.5M CNY | -3.1M CNY | -41.2M CNY |
| Income tax payable | 5.9M CNY | 101.0K CNY | 705.0K CNY |
| Accrued unrecognized tax benefit | 6.6M CNY | 35.0K CNY | -15.8M CNY |
| Operating lease liabilities | -15.9M CNY | -19.3M CNY | -18.1M CNY |
| Net cash used in operating activities | -201.8M CNY | -397.7M CNY | -276.5M CNY |
| Investment in equity investments without readily determinable fair value | -100.0K CNY | ||
| Acquisitions of property, plant and equipment | -56.3M CNY | -150.8M CNY | -113.0M CNY |
| Acquisitions of intangible assets | -30.0K CNY | -10.2M CNY | -4.2M CNY |
| Deposits for the purchases of property, plant and equipment | -35.0M CNY | -249.9M CNY | -2.7M CNY |
| Proceeds from disposal of property, plant and equipment | 7.5M CNY | 310.0K CNY | |
| Proceeds from disposal of subsidiaries | -10.0K CNY | 9.1M CNY | |
| Proceeds from dividend | 3.2M CNY | ||
| Cash distribution from equity method investments | 10.0M CNY | 12.0M CNY | |
| Investment in a joint venture | -102.0M CNY | ||
| Proceeds from disposal of other investment | 27.7M CNY | ||
| Purchase of short - term investment | 134.6M CNY | -204.6M CNY | |
| Proceeds from disposal of short - term investment | 77.3M CNY | ||
| Proceeds from disposal of certain percentage of an equity method investment | 60.0M CNY | ||
| Net cash provided by/(used in) investing activities | 54.0M CNY | -593.4M CNY | -47.7M CNY |
| Proceeds from short-term bank borrowings | 359.2M CNY | 654.7M CNY | 337.7M CNY |
| Proceeds from long-term bank and other borrowings | 94.8M CNY | 1.8B CNY | 110.0M CNY |
| Borrowings from related parties (note 25) | 517.0M CNY | 300.5M CNY | 22.1M CNY |
| Repayment to related parties (note 25) | -468.4M CNY | -335.4M CNY | -61.8M CNY |
| Repayment of short-term bank and other borrowings | -437.1M CNY | -360.3M CNY | -442.9M CNY |
| Repayment of long-term bank and other borrowings | -433.5M CNY | -1.4B CNY | -7.6M CNY |
| Capital injection from a noncontrolling interests in a subsidiary | 61.0M CNY | 300.0M CNY | |
| Proceeds from initial public offering of Concord Healthcare Group Co., Ltd. | 504.2M CNY | 510.5M CNY | 0 CNY |
| Net cash generated from financing activities | 197.2M CNY | 1.1B CNY | 257.7M CNY |
| Effect of foreign exchange rate changes on cash and cash equivalent and restricted cash | 12.4M CNY | -8.3M CNY | -2.4M CNY |
| Net increase (decrease) in cash | 61.7M CNY | 146.6M CNY | -68.9M CNY |
| Income tax paid | -109.0K CNY | -148.0K CNY | -898.0K CNY |
| Interest paid | -183.0M CNY | -188.3M CNY | -152.4M CNY |
| Acquisition of property, plant and equipment, construction in progress and other intangible assets through utilization of deposits | 757.0K CNY | 79.6M CNY | 5.8M CNY |
| Acquisition of property, plant and equipment, construction in progress and other intangible assets included in accrued expense and other liabilities | 285.4M CNY | ||
| Acquisition of property, plant and equipment, construction in progress and other intangible assets included in other long-term liabilities | 10.3M CNY | 0 CNY |
Timeline
- Sep 1988Went public Listed on Toronto Stock Exchange1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCanagold Resources on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9